"The APAC market is expected to witness the fastest growth of any radiopharmaceutical market worldwide"

Australian firm Telix Pharmaceuticals is pioneering advanced radiopharmaceuticals. Recently, the company achieved remarkable success with the global launch of Illuccix, their first commercial product for prostate cancer imaging in 2022.

- Ayesha Siddiqui

This milestone led to an impressive AUD$100 million in revenue for Q1 this year. Dr David N Cade, CEO of Asia Pacific of Telix Pharmaceuticals, shares insights into the company’s vision, future plans, and the regulatory landscape of the radiopharmaceutical sector. Edited excerpts:

Can you introduce the field of radiopharmaceuticals and the activities of Telix Pharma?

Telix is an Australian-headquartered commercia-lstage radiopharmaceutical company. Our targeted radiation imaging and therapy technologies have the potential to transform the way clinicians can find and manage cancer and a number of important rare diseases, inform treatment decisions and deliver personalised therapy in areas of major unmet medical need globally. We’re a therapy company that believes in the concept of precision medicine.

We launched our first commercial product for prostate cancer imaging, Illuccix, in Australia and the United States in 2022 and are helping thousands of patients around the world each week, with the ability to impact the lives of people with cancer increasing every day through commercial products, clinical trials and compassionate use programmes.

We are also building the foundations for longterm sustainable growth to unlock the value in our world-leading, late-stage ‘theranostic’ (therapeutic and diagnostic) pipeline. With more than 20 clinical studies underway worldwide (including partnered investigator-led studies), Telix’s core pipeline aims to address significant unmet medical needs in prostate, kidney, brain, and blood cancers as well as a range of hard-to-treat immunologic and rare diseases.